NRx Pharmaceuticals (NASDAQ:NRXP) reached a potentially significant regulatory milestone after announcing that the U.S. Food and Drug Administration completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine without identifying any major deficiencies related to the drug itself. Instead, the remaining review item involves certification of the product's luer lock vial packaging, a manufacturing documentation issue rather than concerns involving safety, efficacy, labeling, chemistry, manufacturing controls, or the ketamine formulation.